首页 > 最新文献

Current diabetes reviews最新文献

英文 中文
Association between Low-carbohydrate Diets and 10-year Atherosclerosis Cardiovascular Disease Risk: Data from the National Health and Nutrition Examination Survey. 低碳水化合物饮食与10年动脉粥样硬化心血管疾病风险的关系:来自全国健康和营养检查调查的数据。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-20 DOI: 10.2174/0115733998411207251130184836
Yipeng Du, Hong Ouyang, Huiyong Wang, Jian Shi, Yuanqing Li, Huidong Long, Xiudi Pan

Introduction: To evaluate the association between low-carbohydrate diet (LCD) score and atherosclerotic cardiovascular disease (ASCVD) among individuals with type 2 diabetes mellitus (T2DM).

Methods: A total of 3685 participants from the National Health and Nutrition Examination Survey database 2007-2020 were included in this cross-sectional study. The primary outcome of this study was the 10-year ASCVD risk. We used the weighted logistic regression models to assess the association between LCD score and 10-year ASCVD risk. Stratified analysis based on age, body mass index (BMI), hypertension, dyslipidemia, and chronic kidney disease (CKD) was conducted. Odds ratio (OR) and 95% confidence interval (CI) were calculated.

Results: After adjusting for all confounding factors, when LCD was treated as a continuous variable, the findings revealed an inverse association between LCD and 10-year ASCVD risk among individuals with T2DM (OR=0.97, 95% CI: 0.94-0.99, p=0.045). When LCD was stratified into tertiles, individuals in the highest tertiles of LCD exhibited a negative association with 10-year ASCVD risk compared to those in the first tertile (OR=0.66, 95% CI: 0.46-0.95, p=0.025). Subgroup analysis indicated an negative association between high tertiles of LCD and 10-years ASCVD risk in individuals with T2DM who had a BMI≥25kg/m2 (OR=0.66, 95% CI: 0.45-0.97, p<0.05), hypertension (OR=0.61, 95% CI: 0.40-0.91, p<0.05) and dyslipidemia (OR=0.64, 95% CI: 0.43-0.95, p<0.05), and BMI<25kg/m2 with history of CKD (OR=0.64, 95% CI: 0.42-0.96, p<0.05).

Discussion: The inverse association observed between LCD score and ASCVD risk in individuals with T2DM may be partly explained by improved glycemic control, reduced insulin resistance, and favorable lipid profile changes often associated with lower carbohydrate intake. Notably, the protective effect was more pronounced in individuals with additional metabolic comorbidities, such as obesity, hypertension, and dyslipidemia, suggesting that these subgroups may derive greater cardiovascular benefit from LCD-style eating patterns. However, the cross-sectional nature of our study precludes causal inference. Additionally, dietary intake was self-reported and subject to recall bias, and residual confounding cannot be fully ruled out. Despite these limitations, our findings contribute to the growing body of evidence supporting dietary carbohydrate modification as a potential strategy in cardiovascular risk management among patients with T2DM.

Conclusion: Our study found an inverse association between LCD score and 10-year ASCVD risk in individuals with T2DM. These findings may provide a reference for future research and inform dietary recommendations, though causal relationships cannot be established due to the cross-sectional design.

目的:探讨低碳水化合物饮食(LCD)评分与2型糖尿病(T2DM)患者动脉粥样硬化性心血管疾病(ASCVD)的关系。方法:从2007-2020年全国健康与营养检查调查数据库中共纳入3685名参与者。这项研究的主要结果是10年ASCVD风险。我们使用加权逻辑回归模型来评估LCD评分与10年ASCVD风险之间的关系。根据年龄、体重指数(BMI)、高血压、血脂异常和慢性肾脏疾病(CKD)进行分层分析。计算优势比(OR)和95%置信区间(CI)。结果:在对所有混杂因素进行校正后,当LCD作为连续变量处理时,结果显示LCD与T2DM患者10年ASCVD风险呈负相关(OR=0.97, 95% CI: 0.94-0.99, p=0.045)。当LCD分层时,与第一分位的个体相比,LCD最高分位的个体与10年ASCVD风险呈负相关(OR=0.66, 95% CI: 0.46-0.95, p=0.025)。亚组分析显示,BMI≥25kg/m2的T2DM患者LCD评分与10年ASCVD风险呈负相关(OR=0.66, 95% CI: 0.45-0.97)。讨论:T2DM患者LCD评分与ASCVD风险呈负相关的部分原因可能是血糖控制的改善、胰岛素抵抗的降低以及与低碳水化合物摄入相关的有利血脂变化。值得注意的是,这种保护作用在患有其他代谢合并症(如肥胖、高血压和血脂异常)的个体中更为明显,这表明这些亚群可能从lcd饮食模式中获得更大的心血管益处。然而,我们研究的横断面性质排除了因果推理。此外,饮食摄入量是自我报告的,受回忆偏差的影响,残留的混杂因素不能完全排除。尽管存在这些局限性,我们的研究结果为越来越多的证据支持饮食碳水化合物改变作为T2DM患者心血管风险管理的潜在策略做出了贡献。结论:我们的研究发现,在T2DM患者中,LCD评分与10年ASCVD风险呈负相关。这些发现可能为未来的研究提供参考,并为饮食建议提供信息,尽管由于横断面设计,不能建立因果关系。
{"title":"Association between Low-carbohydrate Diets and 10-year Atherosclerosis Cardiovascular Disease Risk: Data from the National Health and Nutrition Examination Survey.","authors":"Yipeng Du, Hong Ouyang, Huiyong Wang, Jian Shi, Yuanqing Li, Huidong Long, Xiudi Pan","doi":"10.2174/0115733998411207251130184836","DOIUrl":"https://doi.org/10.2174/0115733998411207251130184836","url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate the association between low-carbohydrate diet (LCD) score and atherosclerotic cardiovascular disease (ASCVD) among individuals with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>A total of 3685 participants from the National Health and Nutrition Examination Survey database 2007-2020 were included in this cross-sectional study. The primary outcome of this study was the 10-year ASCVD risk. We used the weighted logistic regression models to assess the association between LCD score and 10-year ASCVD risk. Stratified analysis based on age, body mass index (BMI), hypertension, dyslipidemia, and chronic kidney disease (CKD) was conducted. Odds ratio (OR) and 95% confidence interval (CI) were calculated.</p><p><strong>Results: </strong>After adjusting for all confounding factors, when LCD was treated as a continuous variable, the findings revealed an inverse association between LCD and 10-year ASCVD risk among individuals with T2DM (OR=0.97, 95% CI: 0.94-0.99, p=0.045). When LCD was stratified into tertiles, individuals in the highest tertiles of LCD exhibited a negative association with 10-year ASCVD risk compared to those in the first tertile (OR=0.66, 95% CI: 0.46-0.95, p=0.025). Subgroup analysis indicated an negative association between high tertiles of LCD and 10-years ASCVD risk in individuals with T2DM who had a BMI≥25kg/m2 (OR=0.66, 95% CI: 0.45-0.97, p<0.05), hypertension (OR=0.61, 95% CI: 0.40-0.91, p<0.05) and dyslipidemia (OR=0.64, 95% CI: 0.43-0.95, p<0.05), and BMI<25kg/m2 with history of CKD (OR=0.64, 95% CI: 0.42-0.96, p<0.05).</p><p><strong>Discussion: </strong>The inverse association observed between LCD score and ASCVD risk in individuals with T2DM may be partly explained by improved glycemic control, reduced insulin resistance, and favorable lipid profile changes often associated with lower carbohydrate intake. Notably, the protective effect was more pronounced in individuals with additional metabolic comorbidities, such as obesity, hypertension, and dyslipidemia, suggesting that these subgroups may derive greater cardiovascular benefit from LCD-style eating patterns. However, the cross-sectional nature of our study precludes causal inference. Additionally, dietary intake was self-reported and subject to recall bias, and residual confounding cannot be fully ruled out. Despite these limitations, our findings contribute to the growing body of evidence supporting dietary carbohydrate modification as a potential strategy in cardiovascular risk management among patients with T2DM.</p><p><strong>Conclusion: </strong>Our study found an inverse association between LCD score and 10-year ASCVD risk in individuals with T2DM. These findings may provide a reference for future research and inform dietary recommendations, though causal relationships cannot be established due to the cross-sectional design.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of RAGE Inhibitors from Curcuma caesia Roxb: Implications in Treatment against Diabetic Complications. 姜黄中RAGE抑制剂的鉴定:对糖尿病并发症的治疗意义。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-20 DOI: 10.2174/0115733998416568251122070701
Priyakshi Nath, Anil K Pasupulati, Rupshikha Nath, Rajat Nath, Mriganka Das, Deepa Nath, Jagajjit Sahu, Sibashish Kityania, Anupam Das Talukdar

Introduction: Diabetic nephropathy (DN) is a progressive renal complication that significantly contributes to end-stage renal disease. Hyperglycaemia contributes to the formation of advanced glycation end-products (AGEs). The interaction between AGEs and their receptor (RAGE) plays a key role in the progression of DN. RAGE activation increases oxidative stress and promotes inflammation, thereby evoking cellular and molecular damage. Together, these events result in kidney injury and varying degrees of proteinuria. This study aims to evaluate the drug-like properties of potential natural compounds derived from Curcuma caesia and their potential effectiveness against DN.

Methods: This study investigates the antioxidant properties of Curcuma caesia (CC) rhizome extracts, alongside in silico methodologies including molecular docking, QSAR, and ADMET analysis to identify potential metabolites.

Results: In this study, we examined the potential of phytochemicals identified from the rhizome extracts of Curcuma caesia (CC) that may mimic AGEs and inhibit RAGE activation. We assessed whether these phytochemicals could prevent ROS accumulation and inflammation, thereby providing renoprotection in a diabetic milieu. Using molecular docking and ADMET analysis, we identified two compounds, Lappaol A and Piperaduncin B, in the methanolic extract of CC, which demonstrated a stronger affinity for interacting with RAGE than the AGE compound MODIC and the RAGE inhibitor Azeliragon.

Discussion: Since the interaction between AGEs and RAGE contributes to major pathological events in the development of DN, inhibiting this interaction could be a valuable therapeutic strategy against DN and other AGE-mediated pathologies such as retinopathy and neuropathy. Virtual screening of the identified compounds revealed that Lappaol A and Piperaduncin B effectively bind to RAGE and may interrupt RAGE activation, thereby potentially slowing the progression of DN.

Conclusion: These natural compounds exhibited promising drug-like characteristics against the target protein RAGE and may serve as lead compounds for the development of RAGE inhibitors. The study recommends further in vitro and in vivo investigations to assess the therapeutic potential of these identified compounds in the treatment of diabetic nephropathy.

简介:糖尿病肾病(DN)是一种进行性肾脏并发症,对终末期肾脏疾病有重要影响。高血糖有助于晚期糖基化终产物(AGEs)的形成。AGEs与其受体RAGE之间的相互作用在DN的进展中起关键作用。RAGE激活会增加氧化应激,促进炎症,从而引起细胞和分子损伤。这些事件共同导致肾损伤和不同程度的蛋白尿。本研究旨在评价莪术中潜在天然化合物的类药物性质及其对DN的潜在疗效。方法:采用分子对接、QSAR和ADMET分析等方法,研究莪术根茎提取物的抗氧化性能。结果:在本研究中,我们检测了从莪术(Curcuma caesia, CC)根茎提取物中鉴定的植物化学物质的潜力,这些化学物质可能模拟AGEs并抑制RAGE的激活。我们评估了这些植物化学物质是否可以防止ROS积累和炎症,从而在糖尿病环境中提供肾保护。通过分子对接和ADMET分析,我们在CC的甲醇提取物中发现了两个化合物,Lappaol A和Piperaduncin B,它们比AGE化合物MODIC和RAGE抑制剂Azeliragon具有更强的与RAGE相互作用的亲和力。讨论:由于age和RAGE之间的相互作用有助于DN发展中的主要病理事件,抑制这种相互作用可能是针对DN和其他age介导的病理(如视网膜病变和神经病变)的有价值的治疗策略。虚拟筛选鉴定的化合物显示,Lappaol A和Piperaduncin B有效地结合RAGE,并可能中断RAGE的激活,从而潜在地减缓DN的进展。结论:这些天然化合物对靶蛋白RAGE具有良好的药物样特性,可作为RAGE抑制剂的先导化合物。该研究建议进一步的体外和体内研究,以评估这些已确定的化合物在治疗糖尿病肾病方面的治疗潜力。
{"title":"Identification of RAGE Inhibitors from <i>Curcuma caesia</i> Roxb: Implications in Treatment against Diabetic Complications.","authors":"Priyakshi Nath, Anil K Pasupulati, Rupshikha Nath, Rajat Nath, Mriganka Das, Deepa Nath, Jagajjit Sahu, Sibashish Kityania, Anupam Das Talukdar","doi":"10.2174/0115733998416568251122070701","DOIUrl":"https://doi.org/10.2174/0115733998416568251122070701","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic nephropathy (DN) is a progressive renal complication that significantly contributes to end-stage renal disease. Hyperglycaemia contributes to the formation of advanced glycation end-products (AGEs). The interaction between AGEs and their receptor (RAGE) plays a key role in the progression of DN. RAGE activation increases oxidative stress and promotes inflammation, thereby evoking cellular and molecular damage. Together, these events result in kidney injury and varying degrees of proteinuria. This study aims to evaluate the drug-like properties of potential natural compounds derived from Curcuma caesia and their potential effectiveness against DN.</p><p><strong>Methods: </strong>This study investigates the antioxidant properties of Curcuma caesia (CC) rhizome extracts, alongside in silico methodologies including molecular docking, QSAR, and ADMET analysis to identify potential metabolites.</p><p><strong>Results: </strong>In this study, we examined the potential of phytochemicals identified from the rhizome extracts of Curcuma caesia (CC) that may mimic AGEs and inhibit RAGE activation. We assessed whether these phytochemicals could prevent ROS accumulation and inflammation, thereby providing renoprotection in a diabetic milieu. Using molecular docking and ADMET analysis, we identified two compounds, Lappaol A and Piperaduncin B, in the methanolic extract of CC, which demonstrated a stronger affinity for interacting with RAGE than the AGE compound MODIC and the RAGE inhibitor Azeliragon.</p><p><strong>Discussion: </strong>Since the interaction between AGEs and RAGE contributes to major pathological events in the development of DN, inhibiting this interaction could be a valuable therapeutic strategy against DN and other AGE-mediated pathologies such as retinopathy and neuropathy. Virtual screening of the identified compounds revealed that Lappaol A and Piperaduncin B effectively bind to RAGE and may interrupt RAGE activation, thereby potentially slowing the progression of DN.</p><p><strong>Conclusion: </strong>These natural compounds exhibited promising drug-like characteristics against the target protein RAGE and may serve as lead compounds for the development of RAGE inhibitors. The study recommends further in vitro and in vivo investigations to assess the therapeutic potential of these identified compounds in the treatment of diabetic nephropathy.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic Modifications and Their Role in Type 1 Diabetes Development: A Review. 表观遗传修饰及其在1型糖尿病发展中的作用:综述。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-20 DOI: 10.2174/0115733998399336251122042738
Jenner Chrystian Veríssimo de Azevedo, Fernando Liberalino Fernandes, Tayline Dantas Rodrigues, Iluska Almeida Carneiro Martins de Medeiros, Vania Sousa Andrade, Joselio Maria Galvão de Araújo, Fabiana Lima Bezerra, Christiane Medeiros Bezerra, Thales Allyrio Araújo de Medeiros Fernandes, José Veríssimo Fernandes

Introduction: Type 1 Diabetes Mellitus (T1DM) is a multifactorial autoimmune disease marked by pancreatic β-cell destruction and insulin deficiency. Its pathogenesis involves genetic predisposition, environmental exposures, and epigenetic modifications. This review examines how epigenetic mechanisms, including DNA methylation, histone modifications, and noncoding RNAs, contribute to T1DM and their potential as biomarkers and therapeutic targets.

Methods: A comprehensive literature review was conducted using PubMed, Scopus, Web of Knowledge, and Google Scholar. Studies on DNA methylation, histone modifications, and noncoding RNA expression in T1DM patients and experimental models were analyzed to identify mechanisms linking epigenetic mechanisms to disease progression.

Results: Epigenetic alterations, including abnormal DNA methylation, histone modifications, and dysregulated non-coding RNAs, play central roles in immune imbalance and β-cell dysfunction. DNA methylation affects genes involved in immune regulation, insulin synthesis, and β-cell survival. Non-coding RNAs regulate transcriptional and inflammatory pathways, while histone modifications alter chromatin accessibility, further contributing to β-cell loss.

Discussion: Epigenetic mechanisms mediate interactions between genetic risk and environmental triggers, shaping autoimmunity and disease heterogeneity. These findings underscore their relevance for early detection and targeted interventions in T1DM.

Conclusion: Epigenetic changes form a critical link between genetics, environment, and immune dysfunction in T1DM. By regulating immune responses and β-cell integrity, they drive disease onset and progression. Their study provides opportunities for predictive biomarkers and innovative therapies aimed at reprogramming epigenetic pathways to restore immune tolerance and preserve β-cell function.

1型糖尿病(T1DM)是一种以胰腺β细胞破坏和胰岛素缺乏为特征的多因素自身免疫性疾病。其发病机制涉及遗传易感性、环境暴露和表观遗传修饰。本文综述了表观遗传机制,包括DNA甲基化、组蛋白修饰和非编码rna,如何促进T1DM及其作为生物标志物和治疗靶点的潜力。方法:采用PubMed、Scopus、Web of Knowledge、谷歌Scholar等数据库进行文献综述。分析了T1DM患者和实验模型中DNA甲基化、组蛋白修饰和非编码RNA表达的研究,以确定将表观遗传机制与疾病进展联系起来的机制。结果:表观遗传改变,包括异常的DNA甲基化、组蛋白修饰和非编码rna失调,在免疫失衡和β细胞功能障碍中起核心作用。DNA甲基化影响参与免疫调节、胰岛素合成和β细胞存活的基因。非编码rna调节转录和炎症途径,而组蛋白修饰改变染色质可及性,进一步导致β细胞损失。讨论:表观遗传机制介导遗传风险和环境触发因素之间的相互作用,形成自身免疫和疾病异质性。这些发现强调了它们与T1DM早期发现和有针对性干预的相关性。结论:表观遗传改变在T1DM的遗传、环境和免疫功能障碍之间形成了关键的联系。通过调节免疫反应和β细胞的完整性,它们驱动疾病的发生和发展。他们的研究为预测性生物标志物和创新疗法提供了机会,旨在重编程表观遗传途径,以恢复免疫耐受和保持β细胞功能。
{"title":"Epigenetic Modifications and Their Role in Type 1 Diabetes Development: A Review.","authors":"Jenner Chrystian Veríssimo de Azevedo, Fernando Liberalino Fernandes, Tayline Dantas Rodrigues, Iluska Almeida Carneiro Martins de Medeiros, Vania Sousa Andrade, Joselio Maria Galvão de Araújo, Fabiana Lima Bezerra, Christiane Medeiros Bezerra, Thales Allyrio Araújo de Medeiros Fernandes, José Veríssimo Fernandes","doi":"10.2174/0115733998399336251122042738","DOIUrl":"https://doi.org/10.2174/0115733998399336251122042738","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 Diabetes Mellitus (T1DM) is a multifactorial autoimmune disease marked by pancreatic β-cell destruction and insulin deficiency. Its pathogenesis involves genetic predisposition, environmental exposures, and epigenetic modifications. This review examines how epigenetic mechanisms, including DNA methylation, histone modifications, and noncoding RNAs, contribute to T1DM and their potential as biomarkers and therapeutic targets.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted using PubMed, Scopus, Web of Knowledge, and Google Scholar. Studies on DNA methylation, histone modifications, and noncoding RNA expression in T1DM patients and experimental models were analyzed to identify mechanisms linking epigenetic mechanisms to disease progression.</p><p><strong>Results: </strong>Epigenetic alterations, including abnormal DNA methylation, histone modifications, and dysregulated non-coding RNAs, play central roles in immune imbalance and β-cell dysfunction. DNA methylation affects genes involved in immune regulation, insulin synthesis, and β-cell survival. Non-coding RNAs regulate transcriptional and inflammatory pathways, while histone modifications alter chromatin accessibility, further contributing to β-cell loss.</p><p><strong>Discussion: </strong>Epigenetic mechanisms mediate interactions between genetic risk and environmental triggers, shaping autoimmunity and disease heterogeneity. These findings underscore their relevance for early detection and targeted interventions in T1DM.</p><p><strong>Conclusion: </strong>Epigenetic changes form a critical link between genetics, environment, and immune dysfunction in T1DM. By regulating immune responses and β-cell integrity, they drive disease onset and progression. Their study provides opportunities for predictive biomarkers and innovative therapies aimed at reprogramming epigenetic pathways to restore immune tolerance and preserve β-cell function.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Link between Evening Chronotypes and T2DM among South Indians: A Cross-Sectional Study. 探索南印度人夜间睡眠类型与2型糖尿病之间的联系:一项横断面研究
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-15 DOI: 10.2174/0115733998406914251104020940
Meghana Belagula Siddaraju, Akalu Srinivas Kamakshi Shriya, Sri Ram Murugesh, Varun Thej Reddy, Arun Gopi, Nimrah Fathima

Introduction: Chronotype refers to an individual's circadian preference in biological and behavioral rhythm relative to the external light-dark cycle. light-dark cycle. Evening chronotype is associated with increased diabetes risk, probably due to inappropriate eating habits, reduced physical activity, and altered sleeping habits. This study aims to find an association between evening chronotropic and diabetes.

Methods: A cross-sectional study was conducted in the General Medicine department over six months. 201 patients satisfying the study criteria were included. Horne-Ostberg Morningness- Eveningness Questionnaire (MEQ), blood samples, sleep quality, and anthropometric indicators were obtained. Postprandial blood sugar (PPBS), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), Total cholesterol (TC), triglycerides (TGs), High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoproteins (VLDL) were measured with standard techniques. A univariate logistic regression analysis, along with post-hoc tests, was employed to find the role of independent variables on each chronotype.

Results: Among the 81 evening chronotypes, 85.1% were diabetics, the mean HDL value in the evening chronotypes was 35.2 mg/dl, significantly (p<0.001) lower than the other two chronotypes. Waist-to-hip ratio (WHR) and body mass index (BMI) were significantly higher in the evening chronotype p= 0.011, p<0.001, respectively. The mean FBS, PPBS, and HbA1c values (170.07 mg/dL, 242 mg/dL, and 8.95%) were higher among evening chronotypes and were statistically significant (p<0.001).

Discussion: Findings highlight that evening chronotypes demonstrate poorer glycaemic control, dyslipidaemias, and adverse anthropometric indices, suggesting that circadian misalignment may contribute to T2DM progression. Lifestyle modification could be a promising intervention.

Conclusion: Our study suggests Evening chronotypes are more likely to have metabolic dysregulation and poor glycemic control.

时间型是指个体相对于外部光暗周期的生理和行为节律的昼夜偏好。光暗周期。夜间睡眠类型与糖尿病风险增加有关,这可能是由于不适当的饮食习惯、体力活动减少和睡眠习惯改变所致。本研究旨在发现夜间变时与糖尿病之间的关系。方法:在全科进行为期6个月的横断面研究。201例患者符合研究标准。获得霍恩-奥斯伯格早晚性问卷(MEQ)、血液样本、睡眠质量和人体测量指标。采用标准技术测定餐后血糖(PPBS)、空腹血糖(FBS)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、甘油三酯(tg)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)和极低密度脂蛋白(VLDL)。采用单变量逻辑回归分析以及事后检验来发现自变量在每种睡眠类型中的作用。结果:在81名夜间睡眠型患者中,85.1%为糖尿病患者,夜间睡眠型患者的HDL平均值为35.2 mg/dl,显著高于对照组。讨论:研究结果强调,夜间睡眠型患者表现出较差的血糖控制、血脂异常和不利的人体测量指标,表明昼夜节律失调可能导致T2DM进展。改变生活方式可能是一种很有希望的干预措施。结论:我们的研究表明,夜猫子更容易出现代谢失调和血糖控制不良。
{"title":"Exploring the Link between Evening Chronotypes and T2DM among South Indians: A Cross-Sectional Study.","authors":"Meghana Belagula Siddaraju, Akalu Srinivas Kamakshi Shriya, Sri Ram Murugesh, Varun Thej Reddy, Arun Gopi, Nimrah Fathima","doi":"10.2174/0115733998406914251104020940","DOIUrl":"https://doi.org/10.2174/0115733998406914251104020940","url":null,"abstract":"<p><strong>Introduction: </strong>Chronotype refers to an individual's circadian preference in biological and behavioral rhythm relative to the external light-dark cycle. light-dark cycle. Evening chronotype is associated with increased diabetes risk, probably due to inappropriate eating habits, reduced physical activity, and altered sleeping habits. This study aims to find an association between evening chronotropic and diabetes.</p><p><strong>Methods: </strong>A cross-sectional study was conducted in the General Medicine department over six months. 201 patients satisfying the study criteria were included. Horne-Ostberg Morningness- Eveningness Questionnaire (MEQ), blood samples, sleep quality, and anthropometric indicators were obtained. Postprandial blood sugar (PPBS), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), Total cholesterol (TC), triglycerides (TGs), High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoproteins (VLDL) were measured with standard techniques. A univariate logistic regression analysis, along with post-hoc tests, was employed to find the role of independent variables on each chronotype.</p><p><strong>Results: </strong>Among the 81 evening chronotypes, 85.1% were diabetics, the mean HDL value in the evening chronotypes was 35.2 mg/dl, significantly (p<0.001) lower than the other two chronotypes. Waist-to-hip ratio (WHR) and body mass index (BMI) were significantly higher in the evening chronotype p= 0.011, p<0.001, respectively. The mean FBS, PPBS, and HbA1c values (170.07 mg/dL, 242 mg/dL, and 8.95%) were higher among evening chronotypes and were statistically significant (p<0.001).</p><p><strong>Discussion: </strong>Findings highlight that evening chronotypes demonstrate poorer glycaemic control, dyslipidaemias, and adverse anthropometric indices, suggesting that circadian misalignment may contribute to T2DM progression. Lifestyle modification could be a promising intervention.</p><p><strong>Conclusion: </strong>Our study suggests Evening chronotypes are more likely to have metabolic dysregulation and poor glycemic control.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovering New Challenges in the Pharmacological and Non-Pharmacological Management of Insulin Resistance. 胰岛素抵抗的药物和非药物治疗新挑战
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-15 DOI: 10.2174/0115733998379857251113060856
Rina Amelia, Chandra Pranata, Tasia Dewi, Afra Meutia Nasution

Introduction: Insulin resistance has become a serious health problem over time. As people age, the incidence of insulin resistance increases. Genetic factors in families with a history of type 2 diabetes are also key risk factors. In Indonesia, an increase in the prevalence of type 2 diabetes to 8.5% was reported in 2018. This indicates that insulin resistance necessitates comprehensive management, encompassing both pharmacological and non-pharmacological approaches. This systematic review aims to discuss insulin resistance and its management, which can be achieved both pharmacologically through various available drugs and non-pharmacologically by modifying lifestyle habits that can be applied to patients with type 2 diabetes.

Method: Studies examining the comprehensive management of insulin resistance with antidiabetic pharmacological drugs and non-pharmaceutical interventions published between 2018 and 2023 were comprehensively searched using advanced searches on PubMed and Google Scholar, according to the specified inclusion and exclusion criteria.

Results: Twenty studies were selected that met the inclusion criteria and have low risks of bias in most domains.

Discussion: Non-pharmacological therapy, such as lifestyle changes that include a ketogenic diet, a vegetarian diet, a structured exercise intervention program, aerobic exercise, Continuous Positive Airway Pressure (CPAP), and electroacupuncture therapy, can significantly reduce insulin resistance and increase insulin sensitivity. Drugs currently prescribed for type 2 DM stimulate insulin secretion or increase insulin sensitivity.

Conclusion: There are benefits of a plant-based diet, a ketogenic diet, and physical exercise in reducing insulin resistance non-pharmacologically. Meanwhile, pharmacologically, the first drug often given is metformin monotherapy. Combination therapy may be considered if monotherapy does not achieve the therapeutic target.

随着时间的推移,胰岛素抵抗已经成为一个严重的健康问题。随着人们年龄的增长,胰岛素抵抗的发病率也在增加。2型糖尿病家族史的遗传因素也是关键的危险因素。据报道,2018年印度尼西亚2型糖尿病患病率上升至8.5%。这表明胰岛素抵抗需要综合管理,包括药物和非药物方法。本系统综述旨在讨论胰岛素抵抗及其管理,胰岛素抵抗可以通过各种可用药物的药理学方法实现,也可以通过改变生活习惯的非药理学方法实现,这些方法可以应用于2型糖尿病患者。方法:采用PubMed和谷歌Scholar上的高级检索,根据指定的纳入和排除标准,综合检索2018 - 2023年间发表的探讨抗糖尿病药物和非药物干预综合管理胰岛素抵抗的研究。结果:20项研究符合纳入标准,在大多数领域具有低偏倚风险。讨论:非药物治疗,如生活方式的改变,包括生酮饮食、素食饮食、有组织的运动干预计划、有氧运动、持续气道正压通气(CPAP)和电针治疗,可以显著降低胰岛素抵抗和增加胰岛素敏感性。目前治疗2型糖尿病的药物会刺激胰岛素分泌或增加胰岛素敏感性。结论:植物性饮食、生酮饮食和体育锻炼在降低胰岛素抵抗方面具有非药物性的益处。同时,在药理学上,第一种药物通常是二甲双胍单药治疗。如果单药治疗不能达到治疗目标,可以考虑联合治疗。
{"title":"Discovering New Challenges in the Pharmacological and Non-Pharmacological Management of Insulin Resistance.","authors":"Rina Amelia, Chandra Pranata, Tasia Dewi, Afra Meutia Nasution","doi":"10.2174/0115733998379857251113060856","DOIUrl":"https://doi.org/10.2174/0115733998379857251113060856","url":null,"abstract":"<p><strong>Introduction: </strong>Insulin resistance has become a serious health problem over time. As people age, the incidence of insulin resistance increases. Genetic factors in families with a history of type 2 diabetes are also key risk factors. In Indonesia, an increase in the prevalence of type 2 diabetes to 8.5% was reported in 2018. This indicates that insulin resistance necessitates comprehensive management, encompassing both pharmacological and non-pharmacological approaches. This systematic review aims to discuss insulin resistance and its management, which can be achieved both pharmacologically through various available drugs and non-pharmacologically by modifying lifestyle habits that can be applied to patients with type 2 diabetes.</p><p><strong>Method: </strong>Studies examining the comprehensive management of insulin resistance with antidiabetic pharmacological drugs and non-pharmaceutical interventions published between 2018 and 2023 were comprehensively searched using advanced searches on PubMed and Google Scholar, according to the specified inclusion and exclusion criteria.</p><p><strong>Results: </strong>Twenty studies were selected that met the inclusion criteria and have low risks of bias in most domains.</p><p><strong>Discussion: </strong>Non-pharmacological therapy, such as lifestyle changes that include a ketogenic diet, a vegetarian diet, a structured exercise intervention program, aerobic exercise, Continuous Positive Airway Pressure (CPAP), and electroacupuncture therapy, can significantly reduce insulin resistance and increase insulin sensitivity. Drugs currently prescribed for type 2 DM stimulate insulin secretion or increase insulin sensitivity.</p><p><strong>Conclusion: </strong>There are benefits of a plant-based diet, a ketogenic diet, and physical exercise in reducing insulin resistance non-pharmacologically. Meanwhile, pharmacologically, the first drug often given is metformin monotherapy. Combination therapy may be considered if monotherapy does not achieve the therapeutic target.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chain Mediating Role of Illness Perception and Fear of Hypoglycemia in Impaired Hypoglycemic Awareness and Mild Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. 疾病感知和低血糖恐惧在2型糖尿病患者低血糖意识受损和轻度认知障碍中的连锁调节作用
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-13 DOI: 10.2174/0115733998418191251127053922
Mengyao Han, Xiangning Li, Yuying He, Yinshi Kan, Xiaojuan Wan, Lin Liu, Yue Su, Jing Chen, Li Fang, Jinping Wang, Yu Zhang

Introduction: Impaired hypoglycemic awareness (IAH) in type 2 diabetes mellitus (T2DM) is linked to mild cognitive impairment (MCI), but the underlying mechanisms are unclear. This study aimed to explore the chain mediating role of two psychological factors, illness perception (IP) and fear of hypoglycemia (FOH), in the relationship between IAH and MCI.

Methods: A cross-sectional survey of 251 T2DM patients was conducted using convenience sampling at two tertiary hospitals. Data on IAH, IP, FOH, and MCI were collected using standardized questionnaires. Data were analyzed and compared using SPSS 27.0 and AMOS 27.0.

Results: There were significant correlations among IAH, IP, FOH, and MCI. Higher IAH was associated with increased FOH and more negative IP, which were both linked to worse cognitive function. Mediation analysis showed that IAH indirectly affects MCI through three pathways: independently via FOH, independently via IP, and via a chained effect of FOH and IP.

Discussion: The findings underscored that the link between IAH and cognitive decline is not solely physiological, but is substantially mediated by psychological responses. Negative illness perceptions and heightened fear, triggered by the unpredictability of IAH, drive maladaptive behaviors and emotional distress that contribute to worse cognitive outcomes.

Conclusion: The findings highlighted the role of psychological factors in cognitive decline among T2DM patients with IAH. We recommend that future interventions consider the associations between these variables. Diverse interventions aimed at improving IP and FOH levels could help slow cognitive decline in patients with IAH.

2型糖尿病(T2DM)的低血糖意识受损(IAH)与轻度认知障碍(MCI)有关,但其潜在机制尚不清楚。本研究旨在探讨疾病感知(IP)和低血糖恐惧(FOH)两种心理因素在IAH与MCI关系中的链式中介作用。方法:对2所三级医院251例T2DM患者进行方便抽样横断面调查。采用标准化问卷收集IAH、IP、FOH和MCI数据。采用SPSS 27.0和AMOS 27.0对数据进行分析比较。结果:IAH、IP、FOH与MCI有显著相关性。较高的IAH与增加的FOH和更多的负IP相关,这两者都与认知功能恶化有关。中介分析表明,IAH通过三种途径间接影响MCI:独立通过FOH,独立通过IP,以及通过FOH和IP的连锁效应。讨论:研究结果强调,IAH和认知能力下降之间的联系不仅仅是生理上的,而且在很大程度上是由心理反应介导的。由IAH的不可预测性引发的消极疾病认知和恐惧加剧,导致适应不良行为和情绪困扰,从而导致更差的认知结果。结论:研究结果强调了心理因素在伴有IAH的T2DM患者认知能力下降中的作用。我们建议未来的干预措施考虑这些变量之间的关联。旨在改善IP和FOH水平的多种干预措施可能有助于减缓IAH患者的认知能力下降。
{"title":"Chain Mediating Role of Illness Perception and Fear of Hypoglycemia in Impaired Hypoglycemic Awareness and Mild Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.","authors":"Mengyao Han, Xiangning Li, Yuying He, Yinshi Kan, Xiaojuan Wan, Lin Liu, Yue Su, Jing Chen, Li Fang, Jinping Wang, Yu Zhang","doi":"10.2174/0115733998418191251127053922","DOIUrl":"https://doi.org/10.2174/0115733998418191251127053922","url":null,"abstract":"<p><strong>Introduction: </strong>Impaired hypoglycemic awareness (IAH) in type 2 diabetes mellitus (T2DM) is linked to mild cognitive impairment (MCI), but the underlying mechanisms are unclear. This study aimed to explore the chain mediating role of two psychological factors, illness perception (IP) and fear of hypoglycemia (FOH), in the relationship between IAH and MCI.</p><p><strong>Methods: </strong>A cross-sectional survey of 251 T2DM patients was conducted using convenience sampling at two tertiary hospitals. Data on IAH, IP, FOH, and MCI were collected using standardized questionnaires. Data were analyzed and compared using SPSS 27.0 and AMOS 27.0.</p><p><strong>Results: </strong>There were significant correlations among IAH, IP, FOH, and MCI. Higher IAH was associated with increased FOH and more negative IP, which were both linked to worse cognitive function. Mediation analysis showed that IAH indirectly affects MCI through three pathways: independently via FOH, independently via IP, and via a chained effect of FOH and IP.</p><p><strong>Discussion: </strong>The findings underscored that the link between IAH and cognitive decline is not solely physiological, but is substantially mediated by psychological responses. Negative illness perceptions and heightened fear, triggered by the unpredictability of IAH, drive maladaptive behaviors and emotional distress that contribute to worse cognitive outcomes.</p><p><strong>Conclusion: </strong>The findings highlighted the role of psychological factors in cognitive decline among T2DM patients with IAH. We recommend that future interventions consider the associations between these variables. Diverse interventions aimed at improving IP and FOH levels could help slow cognitive decline in patients with IAH.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Beneficial Effects of Combination Therapy With SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus. SGLT-2抑制剂和GLP-1受体激动剂联合治疗2型糖尿病的有益效果
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-13 DOI: 10.2174/0115733998419380251126073540
Aimilianos Kalogeris, Ignatios Ikonomidis, Konstantinos G Kyriakoulis, George Pavlidis, John Thymis, Konstantinos Katogiannis, Aikaterini Kountouri, Loukia Pliouta, Sotirios Pililis, Emmanouil Korakas, Vaia Lambadiari

Type 2 diabetes mellitus is a chronic metabolic disorder associated with microvascular and macrovascular complications. Hyperglycemia and insulin resistance are core pathophysiological components of diabetes, linked to subclinical inflammation and persistent oxidative stress, which result in endothelial dysfunction and subsequent atherogenesis. Nowadays, several arrows in the diabetologist's quiver are available for the management of diabetes, providing flexibility and the ability to adopt a personalized approach tailored to each patient's needs. Two of the most commonly prescribed antidiabetic drugs are sodium-glucose cotransporter 2 inhibitors and glucagon- like peptide-1 receptor agonists. Both agents are associated with beneficial metabolic, cardioand nephro-protective effects independent of their antidiabetic properties; thus, their indications have and are continuously expanding over and beyond the treatment of diabetes. Given that these two drug classes have different mechanisms of action, the use of their combination achieves a synergistic interaction and confers additional benefits. The aim of this review is to provide a summary of current knowledge regarding the use of these two drug classes, shed light on the available evidence on their combination, and discuss future perspectives on optimal therapeutic decisions in clinical practice. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in combination therapy are a promising therapeutic duo and are expected to influence future guidelines and decision-making in everyday clinical practice.

2型糖尿病是一种伴有微血管和大血管并发症的慢性代谢性疾病。高血糖和胰岛素抵抗是糖尿病的核心病理生理组成部分,与亚临床炎症和持续氧化应激有关,导致内皮功能障碍和随后的动脉粥样硬化。如今,糖尿病专家的箭筒中有几支箭可用于糖尿病的管理,提供了灵活性和采用个性化方法的能力,以适应每个患者的需求。两种最常用的降糖药是钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂。这两种药物都与有益的代谢、心脏和肾脏保护作用相关,独立于它们的抗糖尿病特性;因此,它们的适应症已经并正在不断扩大,超出糖尿病的治疗范围。鉴于这两类药物具有不同的作用机制,它们的联合使用可以实现协同作用并带来额外的益处。这篇综述的目的是提供关于这两类药物使用的当前知识的总结,阐明它们联合使用的现有证据,并讨论临床实践中最佳治疗决策的未来观点。钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂联合治疗是一个很有前途的治疗组合,有望影响日常临床实践中未来的指导方针和决策。
{"title":"The Beneficial Effects of Combination Therapy With SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.","authors":"Aimilianos Kalogeris, Ignatios Ikonomidis, Konstantinos G Kyriakoulis, George Pavlidis, John Thymis, Konstantinos Katogiannis, Aikaterini Kountouri, Loukia Pliouta, Sotirios Pililis, Emmanouil Korakas, Vaia Lambadiari","doi":"10.2174/0115733998419380251126073540","DOIUrl":"10.2174/0115733998419380251126073540","url":null,"abstract":"<p><p>Type 2 diabetes mellitus is a chronic metabolic disorder associated with microvascular and macrovascular complications. Hyperglycemia and insulin resistance are core pathophysiological components of diabetes, linked to subclinical inflammation and persistent oxidative stress, which result in endothelial dysfunction and subsequent atherogenesis. Nowadays, several arrows in the diabetologist's quiver are available for the management of diabetes, providing flexibility and the ability to adopt a personalized approach tailored to each patient's needs. Two of the most commonly prescribed antidiabetic drugs are sodium-glucose cotransporter 2 inhibitors and glucagon- like peptide-1 receptor agonists. Both agents are associated with beneficial metabolic, cardioand nephro-protective effects independent of their antidiabetic properties; thus, their indications have and are continuously expanding over and beyond the treatment of diabetes. Given that these two drug classes have different mechanisms of action, the use of their combination achieves a synergistic interaction and confers additional benefits. The aim of this review is to provide a summary of current knowledge regarding the use of these two drug classes, shed light on the available evidence on their combination, and discuss future perspectives on optimal therapeutic decisions in clinical practice. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in combination therapy are a promising therapeutic duo and are expected to influence future guidelines and decision-making in everyday clinical practice.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the Gut Microbiota in the Treatment of Type 2 Diabetes: Dietary Interventions, Microbial Preparations, and Fecal Transplantation. 针对肠道微生物群治疗2型糖尿病:饮食干预、微生物制剂和粪便移植。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-13 DOI: 10.2174/0115733998411102251127094217
Lingling Ding, Zhiyuan Xi, Yuxi Zou, Shun Li, Daoyi Chen, Yuwei Liu, Junfang Zhao

Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disease worldwide, characterized by hyperglycemia and insulin resistance (IR). Its escalating global prevalence and the associated morbidity and mortality render it a major public health concern. Conventional glucose- lowering therapies frequently entail adverse effects, hypoglycaemia risk, and fail to arrest disease progression. Emerging evidence positions the gut microbiota as a central regulator of glucose homeostasis and insulin sensitivity, suggesting that gut microbiota might be a promising target for T2DM. This review synthesizes current knowledge of microbiota-driven mechanisms, particularly those of the gut microbiota and their metabolites, that precipitate or exacerbate T2DM. It then critically evaluates microbiota-targeted interventions (dietary modulation, probiotics, prebiotics, antibiotic therapy, and fecal microbiota transplantation) as emerging therapeutic or adjunctive strategies to restore glycaemic control by modulating the gut microbial ecosystem. While clinical validation is incomplete, targeting the gut microbiota represents a promising avenue for both prevention and treatment of T2DM.

2型糖尿病(T2DM)是全球最常见的代谢性疾病,以高血糖和胰岛素抵抗(IR)为特征。其全球流行率不断上升以及相关发病率和死亡率使其成为一个重大的公共卫生问题。传统的降糖治疗经常带来不良反应,低血糖的风险,并不能阻止疾病的进展。新出现的证据表明,肠道微生物群是葡萄糖稳态和胰岛素敏感性的中心调节器,这表明肠道微生物群可能是T2DM的一个有希望的靶点。这篇综述综合了微生物群驱动机制的现有知识,特别是肠道微生物群及其代谢物,沉淀或加剧2型糖尿病。然后,它批判性地评估了以微生物群为目标的干预措施(饮食调节、益生菌、益生元、抗生素治疗和粪便微生物群移植)作为通过调节肠道微生物生态系统恢复血糖控制的新兴治疗或辅助策略。虽然临床验证尚不完整,但针对肠道微生物群代表了预防和治疗2型糖尿病的有希望的途径。
{"title":"Targeting the Gut Microbiota in the Treatment of Type 2 Diabetes: Dietary Interventions, Microbial Preparations, and Fecal Transplantation.","authors":"Lingling Ding, Zhiyuan Xi, Yuxi Zou, Shun Li, Daoyi Chen, Yuwei Liu, Junfang Zhao","doi":"10.2174/0115733998411102251127094217","DOIUrl":"https://doi.org/10.2174/0115733998411102251127094217","url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disease worldwide, characterized by hyperglycemia and insulin resistance (IR). Its escalating global prevalence and the associated morbidity and mortality render it a major public health concern. Conventional glucose- lowering therapies frequently entail adverse effects, hypoglycaemia risk, and fail to arrest disease progression. Emerging evidence positions the gut microbiota as a central regulator of glucose homeostasis and insulin sensitivity, suggesting that gut microbiota might be a promising target for T2DM. This review synthesizes current knowledge of microbiota-driven mechanisms, particularly those of the gut microbiota and their metabolites, that precipitate or exacerbate T2DM. It then critically evaluates microbiota-targeted interventions (dietary modulation, probiotics, prebiotics, antibiotic therapy, and fecal microbiota transplantation) as emerging therapeutic or adjunctive strategies to restore glycaemic control by modulating the gut microbial ecosystem. While clinical validation is incomplete, targeting the gut microbiota represents a promising avenue for both prevention and treatment of T2DM.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulin Resistance as an Underlying Cause of Type 2 Diabetes in Adults Born with Low Birth Weight: A Narrative Review. 胰岛素抵抗是低出生体重成人2型糖尿病的潜在原因:一项叙述性综述
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-09 DOI: 10.2174/0115733998390970251115094927
Sana Ahmed, Eram S Rao, Renuka Pathak, Geeta Trilok-Kumar

Insulin, secreted by pancreatic β-cells, regulates blood glucose levels. Insulin resistance (IR), characterized by diminished cellular responsiveness, increases insulin demand, imposing stress on β-cells. This leads to β-cell decompensation, which contributes to the development of type 2 diabetes (T2D). A growing body of evidence connects early-life exposures, such as low birth weight (LBW), to a heightened risk of developing non-communicable diseases (NCDs) such as T2D in adulthood. This comprehensive review synthesizes findings from 15 observational studies identified through a PubMed search to explore the specific biological mechanisms that link LBW to IR and T2D. The paper critically examines several prominent hypotheses, theories, and models that propose how endogenous responses to intrauterine conditions initiate a programming that can lead to lasting structural and functional changes in key metabolic organs. In individuals with fetal programming, the combination of impaired insulin sensitivity and compensatory insulin action is considered a precursor to impaired glucose tolerance and T2D, particularly in those who underwent rapid catch-up growth during childhood. Regular monitoring of LBW individuals can enable early intervention, such as lifestyle changes, to reduce the risk of IR and T2D. However, improving the early environment by providing care for women of reproductive age, especially during pregnancy, is a cost-effective strategy to address LBW and curb the NCD pandemic.

胰岛素由胰腺β细胞分泌,调节血糖水平。胰岛素抵抗(IR),以细胞反应性降低为特征,增加胰岛素需求,对β细胞施加压力。这导致β细胞失代偿,这有助于2型糖尿病(T2D)的发展。越来越多的证据表明,生命早期暴露,如低出生体重(LBW),与成年后患糖尿病等非传染性疾病(NCDs)的风险增加有关。本综述综合了通过PubMed检索确定的15项观察性研究的结果,以探索将LBW与IR和T2D联系起来的特定生物学机制。本文批判性地考察了几个突出的假设、理论和模型,这些假设、理论和模型提出了宫内条件下的内源性反应如何启动一个程序,从而导致关键代谢器官的持久结构和功能变化。在患有胎儿计划生育的个体中,胰岛素敏感性受损和代偿性胰岛素作用的结合被认为是糖耐量和T2D受损的前兆,特别是那些在儿童期经历快速追赶生长的个体。定期监测低体重个体可以进行早期干预,例如改变生活方式,以降低IR和T2D的风险。然而,通过为育龄妇女,特别是在怀孕期间的育龄妇女提供护理,改善早期环境,是解决低生育能力和遏制非传染性疾病大流行的一项具有成本效益的战略。
{"title":"Insulin Resistance as an Underlying Cause of Type 2 Diabetes in Adults Born with Low Birth Weight: A Narrative Review.","authors":"Sana Ahmed, Eram S Rao, Renuka Pathak, Geeta Trilok-Kumar","doi":"10.2174/0115733998390970251115094927","DOIUrl":"https://doi.org/10.2174/0115733998390970251115094927","url":null,"abstract":"<p><p>Insulin, secreted by pancreatic β-cells, regulates blood glucose levels. Insulin resistance (IR), characterized by diminished cellular responsiveness, increases insulin demand, imposing stress on β-cells. This leads to β-cell decompensation, which contributes to the development of type 2 diabetes (T2D). A growing body of evidence connects early-life exposures, such as low birth weight (LBW), to a heightened risk of developing non-communicable diseases (NCDs) such as T2D in adulthood. This comprehensive review synthesizes findings from 15 observational studies identified through a PubMed search to explore the specific biological mechanisms that link LBW to IR and T2D. The paper critically examines several prominent hypotheses, theories, and models that propose how endogenous responses to intrauterine conditions initiate a programming that can lead to lasting structural and functional changes in key metabolic organs. In individuals with fetal programming, the combination of impaired insulin sensitivity and compensatory insulin action is considered a precursor to impaired glucose tolerance and T2D, particularly in those who underwent rapid catch-up growth during childhood. Regular monitoring of LBW individuals can enable early intervention, such as lifestyle changes, to reduce the risk of IR and T2D. However, improving the early environment by providing care for women of reproductive age, especially during pregnancy, is a cost-effective strategy to address LBW and curb the NCD pandemic.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hybrid Deep Learning Framework for Continuous Blood Glucose Monitoring and Gestational Diabetes Risk Prediction. 用于连续血糖监测和妊娠糖尿病风险预测的混合深度学习框架。
IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-09 DOI: 10.2174/0115733998380389251111041618
Kiran Kumar Chanumolu, Muni Nagamani G, Muni Hemalatha G

Background: Gestational diabetes mellitus (GDM) affects almost 10%-12% of pregnancies worldwide, threatening maternal and fetal life. Continuous glucose monitoring (CGM) forms the backbone of managing GDM, and the current methodologies largely disregard physiological and behavioral factors, thereby greatly reducing accuracy and clinical interpretability.

Methods: A hybrid deep learning framework was developed by fusing CGM with multi-sensing modality data, including heart rate, activity levels, sleep patterns, and dietary intake. For data preprocessing, Kalman filtering was applied for temporal alignment, adaptive normalization provided outlier handling and imputation, while the CNN-BiLSTM backbone with attention was harnessed for feature extraction. A Multi-Task Attention Fusion Network (MTAFN) was used to predict glucose values and classify GDM risk simultaneously, while SHAP and dynamic smoothing contributed to interpretability sets.

Results: The framework was validated on an extended OhioT1DM dataset with adaptations for pregnancy. It reached a glucose prediction RMSE of 9.8 mg/dL and a GDM risk classification accuracy of 93%. Compared to competitive approaches, the present solution attained a 25% better accuracy on interpretability and an improvement in sensitivity and specificity of about 4-6% across various physiological conditions.

Discussion: The use of multi-sensing data increased prediction robustness by capturing complex physiological dependencies. The SHAP-based interpretability justified the predictions through a physiological lens. With an attention mechanism for feature weighting, it was possible to identify crucial variables like meal intake and nighttime variability in the workflow sets.

Conclusion: The hybrid framework proposed here is reliable for clinically interpretable continuous glucose monitoring and GDM risk predictions. Its application with high reliability can lead to integrating it within clinical protocols for real-time maternal care sets.

背景:妊娠期糖尿病(GDM)影响全世界近10%-12%的妊娠,威胁孕产妇和胎儿的生命。连续血糖监测(CGM)是管理GDM的支柱,目前的方法在很大程度上忽略了生理和行为因素,从而大大降低了准确性和临床可解释性。方法:通过融合CGM与多传感模式数据,包括心率、活动水平、睡眠模式和饮食摄入量,开发了一个混合深度学习框架。在数据预处理方面,采用卡尔曼滤波进行时序比对,自适应归一化进行离群值处理和归一化,利用CNN-BiLSTM主干网进行特征提取。多任务注意融合网络(Multi-Task Attention Fusion Network, MTAFN)用于预测血糖值并同时对GDM风险进行分类,而SHAP和动态平滑有助于形成可解释性集。结果:该框架在扩展的OhioT1DM数据集上进行了验证,并适应了妊娠。血糖预测RMSE为9.8 mg/dL, GDM风险分类准确率为93%。与竞争性方法相比,目前的解决方案在各种生理条件下的可解释性准确性提高了25%,灵敏度和特异性提高了约4-6%。讨论:通过捕获复杂的生理依赖性,多传感数据的使用增加了预测的稳健性。基于shap的可解释性通过生理角度证明了预测的合理性。有了特征加权的注意机制,就有可能识别工作流集中的关键变量,如膳食摄入量和夜间可变性。结论:本文提出的混合框架对于临床可解释的连续血糖监测和GDM风险预测是可靠的。其高可靠性的应用可以将其整合到实时产妇护理集的临床方案中。
{"title":"Hybrid Deep Learning Framework for Continuous Blood Glucose Monitoring and Gestational Diabetes Risk Prediction.","authors":"Kiran Kumar Chanumolu, Muni Nagamani G, Muni Hemalatha G","doi":"10.2174/0115733998380389251111041618","DOIUrl":"https://doi.org/10.2174/0115733998380389251111041618","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) affects almost 10%-12% of pregnancies worldwide, threatening maternal and fetal life. Continuous glucose monitoring (CGM) forms the backbone of managing GDM, and the current methodologies largely disregard physiological and behavioral factors, thereby greatly reducing accuracy and clinical interpretability.</p><p><strong>Methods: </strong>A hybrid deep learning framework was developed by fusing CGM with multi-sensing modality data, including heart rate, activity levels, sleep patterns, and dietary intake. For data preprocessing, Kalman filtering was applied for temporal alignment, adaptive normalization provided outlier handling and imputation, while the CNN-BiLSTM backbone with attention was harnessed for feature extraction. A Multi-Task Attention Fusion Network (MTAFN) was used to predict glucose values and classify GDM risk simultaneously, while SHAP and dynamic smoothing contributed to interpretability sets.</p><p><strong>Results: </strong>The framework was validated on an extended OhioT1DM dataset with adaptations for pregnancy. It reached a glucose prediction RMSE of 9.8 mg/dL and a GDM risk classification accuracy of 93%. Compared to competitive approaches, the present solution attained a 25% better accuracy on interpretability and an improvement in sensitivity and specificity of about 4-6% across various physiological conditions.</p><p><strong>Discussion: </strong>The use of multi-sensing data increased prediction robustness by capturing complex physiological dependencies. The SHAP-based interpretability justified the predictions through a physiological lens. With an attention mechanism for feature weighting, it was possible to identify crucial variables like meal intake and nighttime variability in the workflow sets.</p><p><strong>Conclusion: </strong>The hybrid framework proposed here is reliable for clinically interpretable continuous glucose monitoring and GDM risk predictions. Its application with high reliability can lead to integrating it within clinical protocols for real-time maternal care sets.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current diabetes reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1